Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is O  [Clear All Filters]
Kobayashi, R., Mitsui, T., Fujita, N., Osumi, T., Aoki, T., Aoki, K., Suzuki, R., Fukuda, T., Miyamoto, T., Kato, K., et al. (2016). Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.Int J Hematol.
Pohlen, M., Groth, C., Sauer, T., Görlich, D., Mesters, R., Schliemann, C., Lenz, G., Müller-Tidow, C., Büchner, T., Berdel, W.E., et al. (2016). Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (⩾60 years).Bone Marrow Transplant.
Franssen, L.E., Raymakers, R.A.P., Buijs, A., Schmitz, M.F., van Dorp, S., Mutis, T., Lokhorst, H.M., and van de Donk, N.W.C.J. (2016). Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.Eur J Haematol.
Beauverd, Y., Roosnek, E., Tirefort, Y., Dantin, C., Ansari, M., Tsopra, O., Masouridi-Levrat, S., and Chalandon, Y. (2016). Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index.Bone Marrow Transplant.
Koenecke, C., Heim, D., van Biezen, A., Heuser, M., Aljurf, M., Kyrcz-Krzemien, S., Volin, L., de Souza, C.A., Gedde-Dahl, T., Sengeloev, H., et al. (2016). Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.Bone Marrow Transplant.
Chandrakasan, S., Marsh, R.A., Uzel, G., Holland, S.M., Shah, K.N., and Bleesing, J. (2016). Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant.J Allergy Clin Immunol.
Varma, A., Saliba, R.M., Torres, H.A., Afrough, A., Hosing, C., Khouri, I.F., Nieto, Y., Shah, N.D., Parmar, S., Bashir, Q., et al. (2016). Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.Bone Marrow Transplant.
Gaballa, S., Saliba, R.M., Srour, S., Lu, G., Brammer, J.E., Shah, N., Bashir, Q., Patel, K., Bock, F., Parmar, S., et al. (2016). Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.Am J Hematol.
Van Den Neste, E., Schmitz, N., Mounier, N., Gill, D., Linch, D., Trneny, M., Bouadballah, R., Radford, J., Bargetzi, M., Ribrag, V., et al. (2016). Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.Bone Marrow Transplant.
Kourelis, T.V., Nasr, S.H., Dispenzieri, A., Kumar, S.K., Gertz, M.A., Fervenza, F.C., Buadi, F.K., Lacy, M.Q., Erickson, S.B., Cosio, F.G., et al. (2016). Outcomes of patients with renal monoclonal immunoglobulin deposition disease.Am J Hematol.
Jain, A.K., and Barton, M.C. (2016). Outside the p53 RING: Transcription Regulation by Chromatin-Bound MDM2.Mol Cell62, 805-807.
Truman, A.M., Tilly, J.L., and Woods, D.C. (2016). Ovarian regeneration: The potential for stem cell contribution in the postnatal ovary to sustained endocrine function.Mol Cell Endocrinol.
Lu, K.-T., Wang, B.-Y., Chi, W.-Y., Chang-Chien, J., Yang, J.-J., Lee, H.-T., Tzeng, Y.-M., and Chang, W.-W. (2016). Ovatodiolide Inhibits Breast Cancer Stem/Progenitor Cells through SMURF2-Mediated Downregulation of Hsp27.Toxins (Basel)8.
Panula, S., Reda, A., Stukenborg, J.-B., Ramathal, C., Sukhwani, M., Albalushi, H., Edsgärd, D., Nakamura, M., Söder, O., Orwig, K.E., et al. (2016). Over Expression of NANOS3 and DAZL in Human Embryonic Stem Cells.Plos One11, e0165268.
Rini, B.I., Tomita, Y., Melichar, B., Ueda, T., Grünwald, V., Fishman, M.N., Uemura, H., Oya, M., Bair, A.H., Andrews, G.I., et al. (2016). Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.Clin Genitourin Cancer.
Abou-El-Enein, M., Elsanhoury, A., and Reinke, P. (2016). Overcoming Challenges Facing Advanced Therapies in the EU Market.Cell Stem Cell19, 293-297.
Wu, X., Tang, W., Marquez, R.T., Li, K., Highfill, C.A., He, F., Lian, J., Lin, J., Fuchs, J.R., Ji, M., et al. (2016). Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.Oncotarget.
McDonald, P.C., Chafe, S.C., and Dedhar, S. (2016). Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.Front Cell Dev Biol4, 27.
Lesueur, L.L., Mir, L.M., and André, F.M. (2016). Overcoming the Specific Toxicity of Large Plasmids Electrotransfer in Primary Cells In Vitro.Mol Ther Nucleic Acids5, e291.
Bryan, J.C., and Verstovsek, S. (2016). Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.Cancer Chemother Pharmacol.
He, Y.-C., Shen, Y., Cao, Y., Tang, F.-Q., Tian, D.-F., Huang, C.-F., Tao, H., Zhou, F.-L., Zhang, B., Song, L., et al. (2016). Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.Cancer Biomark16, 127-135.
Sun, R., Shen, J., Gao, Y., Zhou, Y., Yu, Z., Hornicek, F., Kan, Q., and Duan, Z. (2016). Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.Oncotarget.
Urrutia, M., Fernández, S., González, M., Vilches, R., Rojas, P., Vásquez, M., Kurte, M., Vega-Letter, A.María, Carrión, F., Figueroa, F., et al. (2016). Overexpression of Glutamate Decarboxylase in Mesenchymal Stem Cells Enhances Their Immunosuppressive Properties and Increases GABA and Nitric Oxide Levels.Plos One11, e0163735.
Xiang, Q., Hong, D., Liao, Y., Cao, Y., Liu, M., Pang, J., Zhou, J., Wang, G., Yang, R., Wang, M., et al. (2016). Overexpression of Gremlin1 in Mesenchymal Stem Cells Improves Hindlimb Ischemia in Mice by Enhancing Cell Survival.J Cell Physiol.
Wu, N., Zhang, Y.-L., Wang, H.-T., Li, D.-W., Dai, H.-J., Zhang, Q.-Q., Zhang, J., Ma, Y., Xia, Q., Bian, J.-M., et al. (2016). Overexpression of hepatocyte nuclear factor 4α in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/β-catenin signaling pathway downregulation.Cancer Biol Ther.